Search for: "High v. Economics Laboratory, Inc." Results 21 - 40 of 91
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
11 Oct 2016, 5:13 am
Patent EP 1 296 947 (the '947 Patent) was a patent for a particular crystalline form of Perindopril – the alpha crystalline form - which Servier applied for in 2001, and which was in 2007 held to be invalid for lack of novelty and obviousness in Les Laboratories Servier v Apotex Inc ([2007] EWHC 1538 (Pat), upheld by the Court of Appeal [2008] EWCA Civ 445.) [read post]
5 Jan 2016, 6:08 am by Nancy E. Halpern, DVM, Esq.
The reintroduction of a canine rabies virus variant† or introduction of any nonendemic rabies viruses into a naïve animal population has the potential to change the epizootiology of rabies in the United States, leading to severe health consequences and economic losses (7). [read post]
27 Jun 2015, 9:58 pm by Mark Summerfield
  Such methods have also long been considered patentable in the US, although there has recently been concern that the decision of the Supreme Court in Mayo Collaborative Services v Prometheus Laboratories, Inc has imposed significant limitations on the types of treatment methods that can be patented.The purpose of this article is not to get into the details, but rather to provide an overview of how patent laws protect (or not) medical treatments for readers who may be… [read post]
26 Apr 2015, 6:14 pm
It is a tool to promote innovation which in turn helps the economic system. [read post]
1 Mar 2014, 6:22 am by Legal Reader
., : COMPLAINT AND DEMAND: FOR JURY TRIALPlaintiff, ::v. :: Case No. 1:14-cv-879AbbVie Inc., and :Abbott Laboratories, Inc., ::Defendants. [read post]
9 Jan 2014, 1:37 pm
Md. 2012) (same); New York State Pesticide Coalition, Inc. v. [read post]
28 Apr 2013, 10:39 pm by Shouvik Kumar Guha
Finally, Prashant has reported just some time back on yet another piece of pharmaceutical legislation in India, wherein Symed Labs Ltd. has sued Glenmark Pharmaceuticals Laboratories before the Delhi High Court for allegedly infringing two of its patents, granted for “Novel intermediates for linezolid and related compounds” and for “A novel process for the preparation of linezolid and related compounds” respectively. [read post]
18 Jan 2013, 2:06 pm by Bexis
(citations omitted).Third, the economic incentives are all wrong, as non-manufacturer liability rewards questionable practices by generic manufacturers and penalizes more careful competitors:Careful Drug Co. gets word from the field that its drug, “X”, might cure high blood pressure when a doctor comes to it with a case series. [read post]